Plasma Metabolomic Profiling in Patients with Rheumatoid Arthritis Identifies Biochemical Features Indicative of Quantitative Disease Activity

Background Rheumatoid arthritis (RA) is a chronic, autoimmune disorder characterized by joint inflammation and pain. In patients with RA, metabolomic approaches, i.e., high-throughput profiling of small-molecule metabolites, on plasma or serum has thus far enabled the discovery of biomarkers for clinical subgroups, risk factors, and predictors of treatment response. Despite these recent advancements, the identification of blood metabolites that are predictive of quantitative disease activity remains an important challenge in precision medicine for RA. Herein, we use global plasma metabolomic profiling analyses to detect metabolites associated with, and predictive of, quantitative disease activity in patients with RA.

Methods Ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was performed on a discovery cohort consisting of 128 plasma samples from 64 RA patients. The resulting metabolomic profiles were analyzed with two different strategies to find metabolites associated with Disease Activity Score-28 using C-reactive protein (DAS28-CRP). Mixed-effects regression models were used to identify metabolites differentially abundant between two disease activity groups (‘lower’, DAS28-CRP ≤ 3.2; and ‘higher’, DAS28-CRP > 3.2); and to identify metabolites significantly associated with DAS28-CRP scores. A generalized linear model (GLM) was constructed for estimating DAS28-CRP using plasma metabolite abundances. For associating metabolites with CRP (an indicator of inflammation), metabolites differentially abundant between two patient groups (‘low-CRP’, CRP ≤ 3.0 mg/L; ‘high-CRP’, CRP > 3.0 mg/L) were investigated.

Results We identified 33 metabolites differentially abundant between lower and higher disease activity groups (P < 0.05). Additionally, we identified 51 metabolites associated with DAS28-CRP (P < 0.05). A GLM based upon these 51 metabolites resulted in higher prediction accuracy (mean absolute error [MAE]±SD: 1.51±1.77) compared to a GLM without feature selection (MAE±SD: 2.02±2.21). The predictive value of this feature set was further demonstrated on a validation cohort of twelve plasma samples, wherein we observed a stronger correlation between predicted vs. actual DAS28-CRP (with feature selection: Spearman’s ρ = 0.69, 95% CI: [0.18, 0.90]; without feature selection: Spearman’s ρ = 0.18, 95% CI: [-0.44, 0.68]). Lastly, among all identified metabolites, the abundances of eight were significantly associated with CRP patient groups while controlling for potential confounders (P < 0.05).

Conclusion We demonstrate for the first time the prediction of quantitative disease activity in RA using plasma metabolomes. The metabolites identified herein provide insight into circulating pro-/anti-inflammatory metabolic signatures that can reflect disease activity and inflammatory status in patients with RA.